ClinicalTrials.gg
CompletedNCT04517357Updated Feb 24, 2025

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

A Phase 2 interventional study of Fluzoparib+Apatinib and Fluzoparib in Relapsed Ovarian Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing fluzoparib in Ovarian Neoplasms — 13 open to participants now, 13 under way, 1 of them phase 3. fluzoparib · Ovarian Neoplasms.

Enrollment
8th of 22
100 · median 70
Started
2020
with 1 other
Phase 2
15 of 22
12 open now
Registered
6th of 22
by date
Lead sponsor
7 of 22
Jiangsu HengRui Medicine Co., Ltd.

Among the 22 studies testing fluzoparib in Ovarian Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2020, is one of 15 in phase 2, and was the 6th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 22 studies testing fluzoparib in Ovarian Neoplasms are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About fluzoparib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing fluzoparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, 2-arm Phase 2 study to evaluate the efficacy and safety of Fluzoparib with Apatinib versus Fluzoparib alone, as treatment, in relapsed ovarian cancer patients. The study contains a Safety Lead-in Phase in which the safety and tolerability of Fluzoparib+Apatinib will be assessed prior to the Phase 2 portion of the study.

03

Conditions studied

  • Relapsed Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosed high-grade serous or endometrioid recurrent ovarian,fallopian tube,or peritoneal cancer.
  2. Patients must have received at least 2 previous platinum-containing regimens.
  3. At least one target lesion.
  4. performance status 0-1.
  5. Adequate bone marrow, kidney and liver function.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib.For exploratory cohort ,patients who received PARP inhibitor are eligible;
  2. Prior unless curatively treated and disease-free for > 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix allowed;
  3. Radiation or anti-hormonal therapy or anticancer therapy within 14 days before first administration;
  4. Known to be positive;
  5. Known active virus, or known active virus;
  6. Untreated and/or uncontrolled ;
  7. Patients with clinical symptoms of cancer ascites, pleural effusion, who need to drainage, or who have undergone ascites drainage within 3 months prior to the first administration;
  8. Pregnant or breast-feeding women.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Safety Lead-in or Parallel, Fluzoparib+Apatinib

    Participants will receive Fluzoparib-Apatinib combination until progression

    Drug: Fluzoparib+Apatinib

  • Active comparator
    Fluzoparib monotherapy

    Participants will receive Fluzoparib monotherapy until progression

    Drug: Fluzoparib

  • Other
    Exploratory cohort: Fluzoparib+Apatinib

    Participants who has previously received PARP inhibitor, will receive Fluzoparib-Apatinib combination until progression

    Drug: Fluzoparib+Apatinib

Interventions

06

What researchers measure

Primary outcomes

  1. (Safety Lead-in) dose limited toxicity (DLT) of Fluzoparib+Apatinib in the first cycle

    Time frame: up to 28 days

  2. (Safety Lead-in) Recommended Phase II Dose (RP2D) of Fluzoparib+Apatinib

    Time frame: up to 28 days

  3. (Phase 2) Objective response rate(ORR) in relapsed ovarian cancer patients

    Defined as Objective response rate per RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Assessed up to a maximum of 20 months

  4. (Exploratory research) Objective response rate(ORR) in relapsed ovarian cancer patients

    Defined as Objective response rate per RECIST 1.1 criteria according to Investigator's assessment

    Time frame: Assessed up to a maximum of 20 months

Secondary outcomes

  1. AEs+SAEs

    Adverse Events and Serious Adverse Events

    Time frame: from the first drug administration to within 30 days for the last treatment dose

  2. Progression free survival (PFS)

    Defined as Progression free survival per RECIST 1.1 criteria according to Investigator's assessment

    Time frame: up to 20 months

  3. Disease control rate (DCR)

    Complete response + Partial response + Stable disease (CR+PR+SD) based on RECIST 1.1

    Time frame: up to 20 months

  4. Duration of response (DoR)

    Time from documentation of tumor response to disease progression assessed among patients who had an objective response

    Time frame: up to 20 months

  5. Response rate by RECIST 1.1 criteria

    Time frame: up to 20 months

  6. Response rate by GCIG CA125

    Time frame: up to 20 months

07

Study locations

1 site
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2023, 37 months.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 37 months is close to that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2020
First posted
Aug 18, 2020
StartActual
Oct 16, 2020
Primary completionActual
Nov 30, 2023
CompletionActual
Nov 1, 2024
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04517357
Responsible party
Sponsor
First posted
Aug 18, 2020
Start date
Oct 16, 2020
Primary completion
Nov 30, 2023
Completion
Nov 1, 2024
Last update
Feb 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluzoparib · Apatinib

Start the discussion